Longboard Pharmaceuticals’ Post

🆕 The World Health Organization has unveiled a groundbreaking online platform called #MeDevIS (Medical Devices Information System). This comprehensive database includes 2,301 medical devices, spanning various treatments and diagnoses such as neonatal care, cancer, cardiovascular disease, and diabetes. This new database will serve as a valuable source for industry professionals, regulatory agencies and healthcare providers and researchers. It is the first database of its kind, and was modeled based on WHO experience managing their Priority Medical Devices List (#MDL). MEDEVIS will be continuously expanded to other health technologies, for additional health conditions and diseases. Follow us for regulatory updates and scientific insights! 💻www.toxhub-consulting.com 📩 info@toxhub-consulting.com #ToxHub #Toxicity #Consultancy #MedicalDevices #MDR

The Science (not Fiction) around Ageing – Metformin Belonging to a family of medications called biguanides. Metformin is the generic name of the drug. It is the first choice of medication prescribed by doctors for type 2 diabetes and pre-diabetes, risk factors for developing heart disease, stroke, and other serious medical conditions. It has been in use since the late 1950’s and is considered to be a very safe drug with little in the way of side effects.   Currently there is a major ongoing clinical trial known as The Targeting Ageing with Metformin (TAME) Trial. This is a six-year clinical trial involving over 3,000 individuals. Read more @ https://lnkd.in/ek_QtYqB

Enrollment in our Phase 2 DAZALS clinical trial studying amyotrophic lateral sclerosis (ALS) has closed.    Learn more about the trial here: https://lnkd.in/gZS3BRDg   #ALS #ClinicalTrial #CortisolModulation

Chondrosarcoma often goes undiagnosed until later stages, leaving patients with limited treatment options. Inhibrx is committed to addressing these unmet medical needs with our ozekibart (INBRX-109), currently in a Phase 2 registration-enabling study, ChonDRAgon, for patients with unresectable or metastatic conventional chondrosarcoma. Learn more about how you can participate: //bit.ly/3CGiLBt #Chondrosarcoma #ClinicalTrials #Inhibrx

Learn about the unmet needs in patients with mental health conditions that prescription digital therapeutics (PDTs) may be able to address from Arwen Podesta, MD, ABPN, FASAM, ABIHM. Discover how PDTs are used along with existing therapies in the mental health care space. Watch the K-Cast series to for more information:https://bit.ly/4fErc2l. #ManagedCare #MentalHealthCare #PDT

350 million people worldwide struggle with vision loss due to retinal disorders, yet there are few available treatments for most #RetinalDiseases. At Johnson & Johnson, we dare to envision a world without blindness. That’s why we’re pioneering investigational #GeneTherapies that have the potential to positively impact patients, transform lives, and restore and preserve millions of people’s sight: https://lnkd.in/eQPeKaBz

Did you know, CBG may offer support to those with Parkinson's symptoms by interacting with the endocannabinoid system and potentially providing neuroprotective properties? Individual responses may vary, and more research is needed to fully understand CBG's role in supporting Parkinson's, but preclinical and clinical evidence demonstrate promising results. While research is in the early stages, it is crucial to stay informed and consult healthcare professionals before considering any changes to wellness routines. Join our quest to educate the providers and patients about the impact of the endocannabinoid system by clicking the link in our bio and reading up on the various studies covering CBG. https://lnkd.in/gXymcpUX #CBG #parkinsons #endocannabinoidsystem #cannabigerol #formula30a

Trial Net is an international network of leading academic institutions, endocrinologists, physicians, scientists and healthcare teams at the forefront of type 1 diabetes (T1D) research. They offer risk screening for relatives of people with T1D and innovative clinical studies testing ways to slow down and prevent disease progression. The goal: a future without T1D! Theres a way for YOU to support JDRF and its mission to make T1D no more!!! LINK IN THE COMMENTS!

In this phase I trial, 114 subjects were randomized, 55 (mean age 29 years, 64% female) assigned to the single ascending dose period and 59 (mean age 32 years, 58% female) assigned to the multiple-ascending dose period, of whom 105 completed the trial. The results showed that muvalaplin reduced lipoprotein(a) [Lp(a)] levels by up to 65% without any safety concerns, providing a basis for further clinical development. Learn more about the results of this study on our website. ➡️ https://lnkd.in/eqtcRUfP #R3i #Lipoprotein #Cardiovascular #CardiovascularHealth #CVD #CardiovascularDisease #ResidualCardiovascularRisk #Muvalaplin

I know there are many individuals and organizations who are passionate about helping patients access FDA approved treatments. I'm especially interested in learning more about any efforts from a policy perspective (state or federal) or ANY type of efforts to help support patients being able to access treatments through the FDA accelerated approval pathway when some payers continue to try to say they consider these to be "investigational" and deny patients access. I know there are lots of people working on this - THANK YOU! 🙏 Please help me learn more about any work that has already been done or is underway! #acceleratedapproval #FDA #accesstotreatment National Organization for Rare Disorders ? EveryLife Foundation for Rare Diseases ? Patients Rising ? Patients Rising Now ? Parent Project Muscular Dystrophy ? Muscular Dystrophy Association ? CureDuchenne ? Little Hercules Foundation ? Jett Foundation ?